👋 Hey, let’s get into it. GLP-1 drugs have already come for your appetite, your blood sugar, and roughly half of pharma’s R&D budget.

Now Altimmune says pemvidutide reduced heavy-drinking days in a controlled Phase 2 trial. Patients taking the weekly obesity drug logged about 1.45 fewer heavy-drinking days per week than placebo after 24 weeks.

That does not make it an approved addiction treatment, and the study was small. But it moves the conversation beyond “my friend stopped ordering wine on Ozempic.” GLP-1 biology may be wandering from appetite control into reward control…and happy hour just got a clinical endpoint.

🩸 FDA Approves Freenome’s Colorectal-Cancer Blood Test
Freenome won FDA approval for SimpleScreen CRC, a blood-based screening test for average-risk adults 45 and older that Abbott will commercialize in the U.S. In a study of more than 48,000 people, the test detected 81.1% of colorectal cancers but only 13.7% of advanced precancerous lesions, with 90.4% specificity. A positive result still requires a colonoscopy, and a negative result is not an all-clear. The product’s advantage is not replacing colonoscopy. It is persuading people who currently avoid screening to do something.

🧠 uniQure Gets an FDA Path for Huntington’s Gene Therapy
uniQure says final FDA meeting minutes support using AMT-130’s existing program for an accelerated-approval filing, with U.S. and U.K. submissions planned for the third quarter. The one-time therapy is surgically infused into the brain to lower mutant huntingtin protein. Three-year high-dose data from 12 evaluable patients suggested 75% slower decline on a composite disease scale versus external controls. That is promising, not definitive: the dataset is tiny and nonrandomized. FDA also expects a confirmatory study to be substantially underway before any approval.

😬 FDA Cuts Replimune’s RP1 Response Rate From 33.6% to 15.7%
FDA reviewers are challenging Replimune’s accelerated-approval case for RP1 plus nivolumab in advanced melanoma after PD-1 therapy. Replimune reported a 33.6% response rate and 24.8-month median response duration, but FDA’s primary reanalysis cut those figures to 15.7% and 14.1 months. The bigger issue is attribution: every patient received both drugs, leaving no clean way to determine RP1’s contribution. Shares fell 30% in early trading as investors digested the criticism. An advisory committee will discuss the evidence July 30; its recommendation will not be a final FDA decision.

✂️ GSK Targets $2.5B in Savings While Doubling Phase 3 Starts
GSK is launching a three-year restructuring designed to save £1.9 billion ($2.5 billion) annually by 2029 while more than doubling planned 2026 Phase 3 starts from 10 to over 20. The program will cost £2.4 billion ($3.2 billion), accelerate seven assets across 18 indications, and help prepare for future erosion of the HIV franchise. Management says most savings will support late-stage R&D, although no precise companywide layoff figure was provided.

⚖️ J&J Proposes at Least $5.5B to Resolve Existing Talc Claims
Johnson & Johnson has proposed paying an estimated $5.5 billion to resolve roughly 76,000 existing ovarian-cancer claims involving its talc products. The framework needs 95% participation and is uncapped, meaning the total could rise above $7 billion. It would not cover future claims, and J&J continues to deny that its talc caused cancer; the proposal is not an admission of liability. After courts rejected repeated subsidiary-bankruptcy strategies, the company is trying the traditional litigation tool: a very large check attached to a very high acceptance threshold.

BioNucleus Briefing lands in the inboxes of 1,400+ scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.

Alright, back to the newsletter.

💊 Atea Matches Epclusa With Four Fewer Weeks of Treatment
Atea’s eight-week hepatitis C regimen delivered a 93.5% cure rate in noncirrhotic patients, matching 12 weeks of Epclusa in Phase 3.

🐚 Caldera Finds $278M and a Listing in Synlogic’s Shell
Caldera secured a $278 million private placement and public listing through Synlogic, funding its Phase 2 inflammatory-bowel-disease push into 2029.

💰 Processa Buys Vidya and Raises $200M
Processa acquired Vidya and raised approximately $200 million, pivoting around CNS-penetrant BTK inhibitor VT-7208 and three planned Phase 2 programs.

💸 Oak Hill Finds $175M for Its Angelman Phase 3
Oak Hill Bio’s proposed SPAC deal could deliver $175 million to fund Phase 3 testing of Angelman antisense drug rugonersen.

🏭 Kyverna and ElevateBio Strike Commercial CAR-T Manufacturing Deal
Kyverna partnered with ElevateBio to manufacture commercial and clinical supplies of miv-cel ahead of a planned fourth-quarter BLA completion in stiff person syndrome.

🗑️ AstraZeneca Quietly Prunes Two Homegrown ADCs
AstraZeneca dropped two internally developed ADCs after efficacy and pharmacology concerns, proving oncology’s favorite delivery system occasionally misses its address.

🚀 Biogen’s New Drugs Finally Outgrow Its Legacy MS Business
Biogen’s $1.06 billion growth portfolio surpassed its $767 million legacy MS franchise, although recently acquired products helped push it across the line.

Mosquito-borne disease used to come with a fairly predictable map. That map is getting smudged. Dengue reached a record 14.4 million reported cases across more than 100 countries in 2024, while invasive mosquito species keep finding new climates, shipping routes, and neighborhoods.

The Asian tiger mosquito, Aedes albopictus, is the standout expansion artist. It tolerates cooler conditions than Aedes aegypti and has established populations across much of southern Europe. In 2024, Fano, Italy, recorded 199 locally acquired dengue cases, proof that one imported infection can ignite transmission when local mosquitoes are ready.

Climate matters, but it’s not working alone. Milder winters lengthen mosquito seasons, changing rainfall creates breeding habitat, and urbanization packs people beside standing water. Travel imports pathogens; trade transports eggs. Mosquitoes reviewed the global-expansion strategy and decided regulatory approval was optional.

For biotech, the opportunity (and obligation) is widening. Vaccines may need markets and trial sites outside traditional endemic zones. Diagnostics must separate overlapping fevers quickly. Genomic surveillance, Wolbachia programs, sterile males, and engineered mosquitoes could help public-health teams respond before isolated cases become outbreaks.

Still, spotting a mosquito is not the same as establishing a disease. Transmission requires the vector, pathogen, weather, susceptible people, and control failures to align. The insects are moving quickly; the question is whether surveillance, diagnostics, and prevention can move faster.

That’s what Incyte now expects Opzelura sales to surpass in 2026. Guidance jumped to $1.05B–$1.10B from $750M–$790M after resolving a CMS dispute, although a $246M accounting reversal provided a sizable assist.

Here’s what biotech Redditors are talking about:

😬 Scientists Discover Government Websites Can Also Post Bad Takes
Biotech Redditors were furious after the CDC changed its vaccine-and-autism page to argue that research has not eliminated every theoretical possibility of a connection. That framing does not reflect the weight of evidence, including large studies involving more than one million children. Commenters also worried that search engines and AI tools could amplify the language simply because it appears on a government domain. Scientists spent decades building the evidence base. The website added an asterisk.

🌱 He Left Biotech to Mow Lawns…No Regrets
One anonymous Ph.D. scientist said losing a biotech job pushed them to expand a lawn-care side business that began with a push mower carried in a sedan. Fifteen months later, the operation reportedly includes a truck, two zero-turn mowers, and two trailers. What resonated was not simply leaving biotech. It was trading years of uncertain experiments for work with visible results, more independence, and an endpoint you can see from the sidewalk. Apparently, the grass really was greener in a field with actual grass.

💉 The First Bundibugyo Ebola Vaccine Enters Humans
Oxford dosed the first volunteer with a Bundibugyo Ebola vaccine, beginning a safety-and-immunogenicity study but not a test of outbreak protection.

🫆 A Fugitive Allegedly Built a Biotech Career Under a False Identity
STAT reports a longtime fugitive allegedly worked in biotech under an alias, turning résumé verification into the week’s strangest compliance lesson.

⚖️ Novo Must Face Part of the CagriSema Investor Lawsuit
Novo Nordisk must face part of a CagriSema investor lawsuit tied to dosing disclosures; the ruling did not establish fraud.

🧐 Fertility Clinics Sell Embryos “Younger” Mitochondria
Some fertility clinics are selling donated “young mitochondria” for infertility despite weak evidence, blurring the line between treatment and reproductive experimentation.

👁️ Claris Bio Raises $118M to Replace Corneal Surgery With Eye Drops
Claris Bio raised a $118 million Series B to advance CSB-001, an experimental eye drop for limbal stem cell deficiency. The modified growth factor is designed to stimulate corneal repair, potentially reducing the need for complex donor- or patient-derived cell procedures. An open-label study has enrolled 63 patients, with fuller results expected later this year. Claris plans two pivotal trials totaling approximately 400 patients in 2027. Eye drops have officially applied for the surgery department’s job.

🦠 July 30, 1947: The Scientist Who Helped Identify HIV Is Born
Françoise Barré-Sinoussi was born in Paris on this day in 1947. At the Institut Pasteur, she joined the team that isolated the retrovirus later identified as HIV in 1983, providing the foundation for diagnostic testing, blood screening, and targeted antiviral research. She and Luc Montagnier received half of the 2008 Nobel Prize in Physiology or Medicine for the discovery. Before researchers could transform HIV treatment, they first had to establish exactly what they were fighting.

Thinking back to Altimmune, GLP-1 drugs have now been linked to eating less, drinking less, and making pharma executives spend considerably more. That is an impressive range for one drug class.

Great news for pharma and for patients trying to curb cravings. Less great for your local bar and grill, which may soon launch a GLP-1 pairing menu: one side salad, a glass of air, and a $25 check. At least the margins should be excellent.

That’s all for today. See you Tuesday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead